Who founded LIPAC Oncology?

LIPAC Oncology was founded by Ramachandran "TR" Thirucote, Michael Oefelein in 2016.

How much funding has LIPAC Oncology raised?

LIPAC Oncology has disclosed $372.5K raised across 1 round.

Where is LIPAC Oncology headquartered?

LIPAC Oncology is headquartered in Pomona, US.

LIPAC Oncology

Pomona, US · Founded 2016 · Delaware LLC

Find your way into LIPAC Oncology

284 people in our graph share verified history with the LIPAC Oncology team — schools, employers, funds. One of them is your warm intro.

Bill Pescatellounlockedknows Michael Oefelein · together at Northwestern University (overlapped)

knows the team · via Northwestern University

×5knows the team · via Case Western Reserve University

×5knows the team · via University of Rochester

LIPAC Oncology is a pharmaceutical company developing chemotherapy treatments based on LiPax, a neoliposomal platform for local, targeted delivery of paclitaxel to treat intracavitary carcinomas. Its lead program targets non-muscle invasive bladder cancer, with additional indications in thoracic, upper tract urothelial, peritoneal, and ovarian cancers.

Biotech Healthtech Medical Devices

Founders & leadership

LIPAC Oncology was founded in 2016 by Ramachandran "TR" Thirucote and Michael Oefelein.

Ramachandran "TR" Thirucote inFounding Chairman & Chief Executive OfficerDr. Ramachandran Thirucote is a pharmaceutical scientist with experience in drug formulation and development across multiple dosage forms. He previously led product development at Agouron Pharmaceuticals, directed early-stage pharmaceutical development efforts at SRI International, and served as Principal Investigator on NIH contracts with NIAID and NCI; he is founding chairman and CEO of LIPAC Oncology.

Michael Oefelein inCo-founder & Chief Medical OfficerMichael Oefelein is a board-certified physician and Fellow of the American College of Surgeons with over 15 years of experience in pharmaceutical and device development across urology, oncology, dermatology, and other specialties. He has authored nearly 100 peer-reviewed publications and has led the design and execution of clinical trials, including registration, safety, and regulatory studies for multiple genitourinary and systemic agents.

Willem A RobbertsNamed on SEC filing

Thirucote RamachandranNamed on SEC filing

Reported raises · per SEC filings

Form D private placements

$372.5K disclosed across 1 round · 2020

▶$372.5KraisedJul 2020 · 6 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Willem A RobbertsExecutive Officer, Director
Thirucote RamachandranExecutive Officer, Director

Offering amount: $5M
Amount sold: $372.5K
First sale: Jan 2020
Incorporated: Limited Liability Company, Delaware, 2016
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap

Cancerresearchuk11 shared keywordsCancer Research UK funds research across discovery, detection, prevention and treatment of cancer to improve patient outcomes and extend survival. It operates as a research funder and scientific organization serving academic and clinical researchers.

Companies competing with LIPAC Oncology for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

LIPAC Oncology to Present at Upcoming Investor Conferencesprnewswire.com · Sep 2021

LIPAC Oncology Announces Presentation of Data from Phase 1/2a Study of LiPax in Patients with Highly Recurrent Bladder Cancer - BioSpacebiospace.com · May 2020

LIPAC Oncology Announces Successful Completion of Phase 1 Bladder Cancer Clinical Study and Initiation of Phase 2A Study | Markets Insidermarkets.businessinsider.com · Oct 2019

Frequently asked questions

What does LIPAC Oncology do?: LIPAC Oncology is a pharmaceutical company developing chemotherapy treatments based on LiPax, a neoliposomal platform for local, targeted delivery of paclitaxel to treat intracavitary carcinomas. Its lead program targets non-muscle invasive bladder cancer, with additional indications in thoracic, upper tract urothelial, peritoneal, and ovarian cancers.
Who founded LIPAC Oncology?: LIPAC Oncology was founded by Ramachandran "TR" Thirucote, Michael Oefelein in 2016.
How much funding has LIPAC Oncology raised?: LIPAC Oncology has disclosed $372.5K raised across 1 round.
Where is LIPAC Oncology headquartered?: LIPAC Oncology is headquartered in Pomona, US.